Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Real-world study of intranasal ketamine for use in patients with refractory chronic migraine

Open access

Abstract

Subanesthetic ketamine infusion has been used for managing refractory headache in inpatient or outpatient infusion settings. Intranasal (IN) ketamine may be an alternative option for outpatient care. We performed a retrospective study at a single tertiary headache center to assess the clinical effectiveness and tolerability of IN ketamine in patients with refractory chronic migraine (rCM). Candidates who received IN ketamine between January 2019 and February 2020 were screened through an electronic medical record query. Manual chart reviews and structured phone interviews were conducted upon obtaining informed consent. Among 242 subjects screened, 169 (age 44.3±13.8; female 79.9%) were interviewed. They reported 25.0±8.7 monthly headache days and tried 6.9±3.1 preventive medications. Overall, they used roughly 7.8±7.0 sprays (ie., 78 mg) per day and 11.6±8.9 days per month. Intranasal ketamine was reported as “very effective” in 49.1% and quality of life (QOL) was considered “much better” in 35.5%. However, 74.0% reported at least one adverse event (AE). In this retrospective study, IN ketamine can serve as an acute treatment for rCM by reducing headache intensity and improving QOL with relatively tolerable AEs. Most patients found IN ketamine effective and continued to use it despite these AEs. The study is limited by its single-center design and selection/recall biases. Well-designed prospective placebo-controlled trials are necessary to demonstrate the efficacy and safety of IN ketamine in patients with migraine. What is already known on this topic – Intravenous ketamine, although has been used for chronic pain and refractory headache, is limited to infusion settings. Intranasal ketamine, a more convenient alternative, has not been well-studied for refractory headache. What this study adds – This real-world study describes the usage pattern, effectiveness, and adverse event profiles of intranasal ketamine in patients with refractory chronic migraine. How this study might affect research, practice or policy – Intranasal ketamine is probably effective with minimal adverse events for refractory chronic migraine, but more well-designed studies are needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2022.11.20.22282558

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 17

Metadata

Authors
Yuan, H., Natekar, A., Park, J. S., Lauritsen, C., Viscusi, E. R., & Marmura, M. J.
Affiliations
  • Thomas Jefferson University (US)
  • OhioHealth (US)
  • Rush University (US)
Corresponding author
Marmura, Michael J.
Venue
medRxiv
Publisher
openRxiv
Published
2022-11-22
OpenAlex
W4309653137
Cited by
1
References
30
Citations by year
2023: 1
Type
posted content
Language
en
Open access
Licence
cc-by-nc-nd
Locations
medRxiv (acceptedVersion, cc-by-nc-nd)
Funders
  • Amgen
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries
  • Upsher-Smith
  • University of Cambridge
  • National Institutes of Health
  • Allergan
Topics
  • Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
Keywords
intranasal ketamine, refractory headache, acute migraine treatment, quality of life, adverse events, treatment effectiveness, outpatient care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-world study of intranasal ketamine for use in patients with refractory chronic migraine. https://app.cochat.ai/papers/10.1101/2022.11.20.22282558
The paper
Yuan, H., Natekar, A., Park, J. S., Lauritsen, C., Viscusi, E. R., & Marmura, M. J. (2022). Real-world study of intranasal ketamine for use in patients with refractory chronic migraine. medRxiv. https://doi.org/10.1101/2022.11.20.22282558

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.